Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

Completed

Conditions studied: Prostate Cancer

In brief

The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix

Key facts

Study ID

NCT06462014

Run by

Pfizer

People needed

507

Starts

2024-06-19

Expected to finish

2024-12-13

Last updated by the study team

2025-12-11

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male with ≥ 1 diagnosis for PC
• Had ≥ 2 prescriptions of relugolix on or after the first observed PC diagnosis.
• Index date: the initiation date of relugolix
• At least 18 years old at the index date

You may not qualify if…

• had surgical castration (bilateral orchiectomy) any time before the index date

Where it is running

• Pfizer — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.